专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20130289030A1 NOVEL PHENAZINE DERIVATIVES AND THEIR USES 有权
标题翻译：新型PHENAZINE衍生物及其用途
公开(公告)号：US20130289030A1
公开(公告)日：2013-10-31
申请号：US13997576
申请日：2011-12-22
申请人： Olivier Feron , Olivier Riant , Robert Kiss , Joelle Leclercq , Gabrielle Chataigne , Nicolas Vandelaer , Carole Lamy
发明人： Olivier Feron , Olivier Riant , Robert Kiss , Joelle Leclercq , Gabrielle Chataigne , Nicolas Vandelaer , Carole Lamy
IPC分类号： C07D491/052 , C07D491/153 , C07D491/22 , C07D497/04
CPC分类号： C07D491/052 , C07D241/38 , C07D491/048 , C07D491/107 , C07D491/153 , C07D491/22 , C07D497/04
摘要： The present invention is directed to novel compounds of formula I and their use as anti-angiogenic agents and anti-cancer agents.
摘要翻译：本发明涉及新颖的式I化合物及其作为抗血管生成剂和抗癌剂的用途。

22. 发明授权

US5182273A Spirocyclic N, O derivatives of cyclotriphosphazenes and their use in therapy 失效
标题翻译：环磷酰胺的螺环N，O衍生物及其在治疗中的应用
公开(公告)号：US5182273A
公开(公告)日：1993-01-26
申请号：US780480
申请日：1991-10-22
申请人： Alain Duflos , Jean-Francois Patoiseau , Dennis Bigg , Robert Kiss
发明人： Alain Duflos , Jean-Francois Patoiseau , Dennis Bigg , Robert Kiss
IPC分类号： A61K31/675 , A61P35/00 , C07F9/6593
CPC分类号： C07F9/65815
摘要： The present invention relates to compounds of the Formula I: ##STR1## wherein R is hydrogen, alkyl, cycloalkyl, phenyl, or alkylphenyl, and n is 2 through 4, the production thereof, pharmaceutical compositions thereof, and their use in antineoplastic therapy.
摘要翻译：本发明涉及式I化合物：其中R为氢，烷基，环烷基，苯基或烷基苯基，n为2至4，其制备，其药物组合物及其在抗肿瘤治疗中的用途。

23. 发明申请

US20130116273A1 BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS 有权
标题翻译：用于治疗增生性疾病的β-碳醇衍生物
公开(公告)号：US20130116273A1
公开(公告)日：2013-05-09
申请号：US13704109
申请日：2011-06-24
申请人： Raphael Frederick , Bernard Masereel , Jeremy Reniers , Johan Wouters , Celine Bruyere , Robert Kiss
发明人： Raphael Frederick , Bernard Masereel , Jeremy Reniers , Johan Wouters , Celine Bruyere , Robert Kiss
IPC分类号： A61K31/437 , C07D471/04
CPC分类号： A61K31/437 , C07D471/04
摘要： The invention provides novel beta-carboline derivatives of formulae (Ia) and (Ib) useful in the treatment of proliferative disorders including cancer, intermediates used in their preparation, processes for preparing the same and uses thereof.
摘要翻译：本发明提供了可用于治疗包括癌症在内的增殖性疾病，其制备中使用的中间体，其制备方法及其应用的式（Ia）和（Ib）的新型β-咔啉衍生物。

24. 发明授权

US5643885A Etoposide derivatives, process for preparing them, their use as a medicinal product and their use for the preparation of a medicinal product intended for anti-cancer treatment 失效
标题翻译：依托泊苷衍生物，其制备方法，用作药物的用途及其用于制备用于抗癌治疗的药物的用途
公开(公告)号：US5643885A
公开(公告)日：1997-07-01
申请号：US464646
申请日：1995-06-21
申请人： Jean-Pierre Robin , Robert Kiss , Thierry Imbert
发明人： Jean-Pierre Robin , Robert Kiss , Thierry Imbert
IPC分类号： C07H17/08 , A61K31/70 , A61K31/7042 , A61K31/7048 , A61P35/00 , C07H17/04 , C07H15/26
CPC分类号： C07H17/04
摘要： Compound of the formula (I) in which R' is a hydrogen atom or a radical R and R is an acyl residue. The invention also concerns the use of said compounds in the treatment of cancer and pharmaceutical compositions comprising said compounds. ##STR1##
摘要翻译： PCT No.PCT / FR93 / 01270 Sec。 371日期：1995年6月21日 102（e）日期1995年6月21日PCT提交1993年12月20日PCT公布。公开号WO94 / 14829 日期：1994年7月7日，其中R'为氢原子或基团R和R为酰基残基的式（I）化合物。本发明还涉及所述化合物在治疗癌症中的用途以及包含所述化合物的药物组合物。我

25. 发明授权

US08772265B2 Water soluble curcumin compositions for use in anti-cancer and anti-inflammatory therapy 有权
标题翻译：用于抗癌和抗炎治疗的水溶性姜黄素组合物
公开(公告)号：US08772265B2
公开(公告)日：2014-07-08
申请号：US12995126
申请日：2009-05-26
申请人： Philippe Neven , Didier Serteyn , Robert Kiss , Veronique Mathieu , Didier Cataldo , Natacha Rocks , Eva Scheer
发明人： Philippe Neven , Didier Serteyn , Jacques Delarge , Robert Kiss , Veronique Mathieu , Didier Cataldo , Natacha Rocks
IPC分类号： A01N43/04 , A61K31/715
CPC分类号： B82Y5/00 , A61K31/724 , A61K45/06 , A61K47/6951 , A61K2300/00
摘要： The present invention relates to the medical field. In a first aspect the present invention relates to novel water soluble cyclodextrin-curcumin complexes having a pharmacological activity, in particular an anti-tumor and/or anti-inflammatory activity, and improved physico-chemical properties. In a second aspect, the present invention relates to a method for preparation of said water soluble curcumin derivatives. The invention further relates in a third aspect to a pharmaceutical composition comprising an effective amount of said water soluble curcumin derivatives. In a fourth aspect, the present invention concerns the use of said water soluble cucumin derivatives as a medicament and the use of said water soluble curcumin derivatives for the preparation of a medicament for the treatment of cancer and inflammatory diseases. In a fifth aspect, the present invention relates to the use of a pharmaceutical composition comprising said water soluble curcumin derivatives in the treatment of cancer and inflammatory diseases and to a new pharmaceutical composition comprising said water soluble curcumin derivatives.
摘要翻译：本发明涉及医疗领域。在第一方面，本发明涉及具有药理活性，特别是抗肿瘤和/或抗炎活性以及改善的物理化学性质的新的水溶性环糊精 - 姜黄素复合物。在第二方面，本发明涉及一种制备所述水溶性姜黄素衍生物的方法。本发明在第三方面进一步涉及包含有效量的所述水溶性姜黄素衍生物的药物组合物。在第四方面，本发明涉及所述水溶性姜黄素衍生物作为药物的用途，以及所述水溶性姜黄素衍生物在制备用于治疗癌症和炎性疾病的药物中的用途。在第五方面，本发明涉及包含所述水溶性姜黄素衍生物的药物组合物在治疗癌症和炎性疾病中的用途以及包含所述水溶性姜黄素衍生物的新药物组合物的用途。

26. 发明申请

US20140005220A9 BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS 有权
标题翻译：用于治疗增生性疾病的β-碳醇衍生物
公开(公告)号：US20140005220A9
公开(公告)日：2014-01-02
申请号：US13704109
申请日：2011-06-24
申请人： Raphael Frederick , Bernard Masereel , Jeremy Reniers , Johan Wouters , Celine Bruyere , Robert Kiss
发明人： Raphael Frederick , Bernard Masereel , Jeremy Reniers , Johan Wouters , Celine Bruyere , Robert Kiss
IPC分类号： A61K31/437 , C07D471/04
CPC分类号： A61K31/437 , C07D471/04
摘要： The invention provides novel beta-carboline derivatives of formulae (Ia) and (Ib) useful in the treatment of proliferative disorders including cancer, intermediates used in their preparation, processes for preparing the same and uses thereof.
摘要翻译：本发明提供了可用于治疗包括癌症在内的增殖性疾病，其制备中使用的中间体，其制备方法及其应用的式（Ia）和（Ib）的新型β-咔啉衍生物。

27. 发明授权

US07964575B2 Use of a galectin-1-targeted RNAi-based approach for the treatment of cancer 有权
标题翻译：使用半乳凝素1靶向基于RNAi的方法治疗癌症
公开(公告)号：US07964575B2
公开(公告)日：2011-06-21
申请号：US11911342
申请日：2006-03-09
申请人： Isabelle Camby , Patrick Henriet , Florence Lefranc , Pierre Courtoy , Robert Kiss
发明人： Isabelle Camby , Patrick Henriet , Florence Lefranc , Pierre Courtoy , Robert Kiss
IPC分类号： A61K31/70 , C07H21/04 , C12N15/00
CPC分类号： C12N15/1138 , C12N15/113 , C12N2310/111 , C12N2310/14 , C12N2310/53
摘要： The present invention relates to an RNAi molecule suitable for reducing the expression of galectin-1 containing any of the sequences of SEQ ID NOs: 1-33, and preferably the sequences of SEQ ID NO: 2, 3, or 4, and to the use thereof as a medicament, or for the manufacture of a medicament for treating and/or for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma. The present invention also relates to compositions and methods for treating and for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma, for reducing the migration of tumor cells, preferably cells of glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma, and/or for enhancing the efficacy of cancer therapies for the treatment of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma, selected from the group comprising chemotherapy, radiation therapy, immunotherapy, and/or gene therapy.
摘要翻译：本发明涉及适于降低含有SEQ ID NO：1-33的任何序列，优选SEQ ID NO：2,3或4的序列的半乳凝素-1的表达的RNAi分子，并且涉及或用于制备用于治疗和/或延迟癌症进展的药物，优选神经胶质瘤，胰腺癌，头颈癌，黑素瘤，非小细胞肺癌和非霍奇金淋巴瘤。本发明还涉及用于治疗和延迟癌症，优选神经胶质瘤，胰腺癌，头颈癌，黑素瘤，非小细胞肺癌和非霍奇金淋巴瘤的进展的组合物和方法，用于减少肿瘤细胞，优选胶质瘤细胞，胰腺癌，头颈癌，黑素瘤，非小细胞肺癌和非霍奇金淋巴瘤，和/或用于增强癌症疗法治疗癌症的功效，优选神经胶质瘤，胰腺癌，头颈癌，黑素瘤，非小细胞肺癌和非霍奇金淋巴瘤，选自化疗，放射治疗，免疫治疗和/或基因治疗。

28. 发明申请

US20100120891A1 USE OF A GALECTIN-1-TARGETED RNAI-BASED APPROACH FOR THE TREATMENT OF CANCER 有权
标题翻译：使用GALECTIN-1靶向基于RNAi的方法治疗癌症
公开(公告)号：US20100120891A1
公开(公告)日：2010-05-13
申请号：US11911342
申请日：2006-03-09
申请人： Isabelle Camby , Patrick Henriet , Florence Lefranc , Pierre Courtoy , Robert Kiss
发明人： Isabelle Camby , Patrick Henriet , Florence Lefranc , Pierre Courtoy , Robert Kiss
IPC分类号： A61K31/7105 , C12N5/071 , C12N15/74 , A61K31/711 , A61P35/00 , A61P35/04
CPC分类号： C12N15/1138 , C12N15/113 , C12N2310/111 , C12N2310/14 , C12N2310/53
摘要： The present invention relates to an RNAi molecule suitable for reducing the expression of galectin-1 containing any of the sequences of SEQ ID NOs: 1-33, and preferably the sequences of SEQ ID NO: 2, 3, or 4, and to the use thereof as a medicament, or for the manufacture of a medicament for treating and/or for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma. The present invention also relates to compositions and methods for treating and for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma, for reducing the migration of tumor cells, preferably cells of glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma, and/or for enhancing the efficacy of cancer therapies for the treatment of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma, selected from the group comprising chemotherapy, radiation therapy, immunotherapy, and/or gene therapy.
摘要翻译：本发明涉及适于降低含有SEQ ID NO：1-33的任何序列，优选SEQ ID NO：2,3或4的序列的半乳凝素-1的表达的RNAi分子，并且涉及或用于制备用于治疗和/或延迟癌症进展的药物，优选神经胶质瘤，胰腺癌，头颈癌，黑素瘤，非小细胞肺癌和非霍奇金淋巴瘤。本发明还涉及用于治疗和延迟癌症，优选神经胶质瘤，胰腺癌，头颈癌，黑素瘤，非小细胞肺癌和非霍奇金淋巴瘤的进展的组合物和方法，用于减少肿瘤细胞，优选胶质瘤细胞，胰腺癌，头颈癌，黑素瘤，非小细胞肺癌和非霍奇金淋巴瘤，和/或用于增强癌症疗法治疗癌症的功效，优选神经胶质瘤，胰腺癌，头颈癌，黑素瘤，非小细胞肺癌和非霍奇金淋巴瘤，选自化疗，放射治疗，免疫治疗和/或基因治疗。

29. 发明授权

US5620985A Antimitotic binary alkaloid derivatives from catharanthus roseus 失效
标题翻译：来自长春花的仿制二元生物碱衍生物
公开(公告)号：US5620985A
公开(公告)日：1997-04-15
申请号：US578669
申请日：1996-01-19
申请人： Jean-Claude Jacquesy , Jacques Fahy , Christian Berrier , Dennis Bigg , Marie-Paule Jouannetaud , Fabien Zunino , Anna Kruczynski , Robert Kiss
发明人： Jean-Claude Jacquesy , Jacques Fahy , Christian Berrier , Dennis Bigg , Marie-Paule Jouannetaud , Fabien Zunino , Anna Kruczynski , Robert Kiss
IPC分类号： A61K31/475 , A61P35/00 , C07D519/04
CPC分类号： C07D519/04
摘要： Novel fluorinated derivatives of the vinblastine and vinorelbine family of general formula (1), ##STR1## wherein the symbols have the meanings indicated in the Specification and Claims, and the therapeutically-acceptable salts of these molecules, as well as pharmaceutical compositions thereof. The invention also concerns the application of said compounds in the treatment of a cancer pathology and their methods of preparation.
摘要翻译： PCT No.PCT / FR94 / 00898 Sec。 371日期1996年1月19日 102（e）1996年1月19日PCT PCT 1994年7月19日PCT公布。出版物WO95 / 0331200 日期1995年2月2日通式（1），IMAGE> 1的长春花碱和长春瑞滨家族的新型氟化衍生物，其中符号具有说明书和权利要求书中所示的含义，以及这些分子的治疗上可接受的盐，以及作为其药物组合物。本发明还涉及所述化合物在治疗癌症病理学及其制备方法中的应用。

30. 发明授权

US09181265B2 Substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines as anti-angiogenic and anti-cancer agents 有权
标题翻译：取代的2,3-二氢-1H-苯并[a]吡喃并[2,3-c]吩嗪作为抗血管生成和抗癌剂
公开(公告)号：US09181265B2
公开(公告)日：2015-11-10
申请号：US13997576
申请日：2011-12-22
申请人： Olivier Feron , Olivier Riant , Robert Kiss , Joelle Leclercq , Gabrielle Chataigne , Nicolas Vandelaer , Carole Lamy
发明人： Olivier Feron , Olivier Riant , Robert Kiss , Joelle Leclercq , Gabrielle Chataigne , Nicolas Vandelaer , Carole Lamy
IPC分类号： A61K31/4985 , C07D241/36 , C07D491/052 , C07D241/38 , C07D491/048 , C07D491/107 , C07D491/153 , C07D491/22 , C07D497/04
CPC分类号： C07D491/052 , C07D241/38 , C07D491/048 , C07D491/107 , C07D491/153 , C07D491/22 , C07D497/04
摘要： Novel phenazine derivatives of formula (I) are disclosed. In particular, substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines are disclosed. The compounds can be used as anti-angiogenic and/or anti-tumor agents.
摘要翻译：公开了式（I）的新型吩嗪衍生物。特别地，公开了取代的2,3-二氢-1H-苯并[a]吡喃并[2,3-c]吩嗪。该化合物可用作抗血管生成和/或抗肿瘤剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式